In a significant step toward understanding and combating childhood cancers and congenital disorders, the Gabriella Miller Kids First Pediatric Research Program (Kids First), an initiative of the National Institutes of Health (NIH), has released two comprehensive new datasets. Focusing on childhood
The recent Orphan Drug Designation (ODD) granted by the U.S. Food and Drug Administration (FDA) to Zai Lab Limited for their drug ZL-1310 marks a significant milestone in the fight against small cell lung cancer (SCLC). This promising Delta-like ligand 3 (DLL3) antibody-drug conjugate (ADC) is
Allarity Therapeutics, Inc. has announced the expansion of their Phase 2 clinical trial for stenoparib, a dual PARP/Wnt pathway inhibitor, aimed at treating advanced ovarian cancer. Their recent decision seeks to accelerate the drug's clinical development and work towards FDA regulatory approval.
The human gut microbiome plays a crucial role in overall health, influencing everything from digestion to immune function. Recent advancements in proteo-genomics have provided unprecedented insights into the complex interactions within the gut microbiome. A groundbreaking study has utilized
The latest study from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center provides compelling evidence that CAR T cell therapy does not induce secondary cancers. This finding comes from an extensive analysis of data involving over 700
Polymetastatic cancer, a condition where cancer has spread to more than 10 spots throughout the body, often leaves patients with limited treatment options. Recent advancements in cancer therapy have focused on high-precision radiation treatments to combat this extensive metastasis. Researchers from
